Cargando…

Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group.

A recent report has provided strong evidence for a major prostate cancer susceptibility locus (HPC1) on chromosome 1q24-25 (Smith et al, 1996). Most inherited cancer susceptibility genes function as tumour-suppressor genes (TSGs). Allelic loss or imbalance in tumour tissue is often the hallmark of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunsmuir, W. D., Edwards, S. M., Lakhani, S. R., Young, M., Corbishley, C., Kirby, R. S., Dearnaley, D. P., Dowe, A., Ardern-Jones, A., Kelly, J., Eeles, R. A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063204/
https://www.ncbi.nlm.nih.gov/pubmed/9836474
_version_ 1782137289009266688
author Dunsmuir, W. D.
Edwards, S. M.
Lakhani, S. R.
Young, M.
Corbishley, C.
Kirby, R. S.
Dearnaley, D. P.
Dowe, A.
Ardern-Jones, A.
Kelly, J.
Eeles, R. A.
author_facet Dunsmuir, W. D.
Edwards, S. M.
Lakhani, S. R.
Young, M.
Corbishley, C.
Kirby, R. S.
Dearnaley, D. P.
Dowe, A.
Ardern-Jones, A.
Kelly, J.
Eeles, R. A.
author_sort Dunsmuir, W. D.
collection PubMed
description A recent report has provided strong evidence for a major prostate cancer susceptibility locus (HPC1) on chromosome 1q24-25 (Smith et al, 1996). Most inherited cancer susceptibility genes function as tumour-suppressor genes (TSGs). Allelic loss or imbalance in tumour tissue is often the hallmark of a TSG. Studies of allelic loss have not previously implicated the chromosomal region 1q24-25 in prostate cancer. However, analysis of tumour DNA from cases in prostate cancer families has not been reported. In this study, we have evaluated DNA from tissue obtained from small families [3-5 affected members (n = 17)], sibling pairs (n = 15) and sporadic (n = 40) prostate tumours using the three markers from Smith et al (1996) that defined the maximum multipoint linkage lod score. Although widely spaced (12-50 cM), each marker showed evidence of allelic imbalance in only approximately 7.5% of informative tumours. There was no difference between the familial and sporadic cases. We conclude that the incidence of allelic imbalance at HPC1 is low in both sporadic tumours and small prostate cancer families. In this group of patients, HPC1 is unlikely to be acting as a TSG in the development of prostate cancer. IMAGES:
format Text
id pubmed-2063204
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Nature Publishing Group|1
record_format MEDLINE/PubMed
spelling pubmed-20632042009-09-10 Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group. Dunsmuir, W. D. Edwards, S. M. Lakhani, S. R. Young, M. Corbishley, C. Kirby, R. S. Dearnaley, D. P. Dowe, A. Ardern-Jones, A. Kelly, J. Eeles, R. A. Br J Cancer Research Article A recent report has provided strong evidence for a major prostate cancer susceptibility locus (HPC1) on chromosome 1q24-25 (Smith et al, 1996). Most inherited cancer susceptibility genes function as tumour-suppressor genes (TSGs). Allelic loss or imbalance in tumour tissue is often the hallmark of a TSG. Studies of allelic loss have not previously implicated the chromosomal region 1q24-25 in prostate cancer. However, analysis of tumour DNA from cases in prostate cancer families has not been reported. In this study, we have evaluated DNA from tissue obtained from small families [3-5 affected members (n = 17)], sibling pairs (n = 15) and sporadic (n = 40) prostate tumours using the three markers from Smith et al (1996) that defined the maximum multipoint linkage lod score. Although widely spaced (12-50 cM), each marker showed evidence of allelic imbalance in only approximately 7.5% of informative tumours. There was no difference between the familial and sporadic cases. We conclude that the incidence of allelic imbalance at HPC1 is low in both sporadic tumours and small prostate cancer families. In this group of patients, HPC1 is unlikely to be acting as a TSG in the development of prostate cancer. IMAGES: Nature Publishing Group|1 1998-12 /pmc/articles/PMC2063204/ /pubmed/9836474 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Dunsmuir, W. D.
Edwards, S. M.
Lakhani, S. R.
Young, M.
Corbishley, C.
Kirby, R. S.
Dearnaley, D. P.
Dowe, A.
Ardern-Jones, A.
Kelly, J.
Eeles, R. A.
Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group.
title Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group.
title_full Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group.
title_fullStr Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group.
title_full_unstemmed Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group.
title_short Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group.
title_sort allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, hpc1. crc/bpg uk familial prostate cancer study collaborators. cancer research campaign/british prostate group.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063204/
https://www.ncbi.nlm.nih.gov/pubmed/9836474
work_keys_str_mv AT dunsmuirwd allelicimbalanceinfamilialandsporadicprostatecancerattheputativehumanprostatecancersusceptibilitylocushpc1crcbpgukfamilialprostatecancerstudycollaboratorscancerresearchcampaignbritishprostategroup
AT edwardssm allelicimbalanceinfamilialandsporadicprostatecancerattheputativehumanprostatecancersusceptibilitylocushpc1crcbpgukfamilialprostatecancerstudycollaboratorscancerresearchcampaignbritishprostategroup
AT lakhanisr allelicimbalanceinfamilialandsporadicprostatecancerattheputativehumanprostatecancersusceptibilitylocushpc1crcbpgukfamilialprostatecancerstudycollaboratorscancerresearchcampaignbritishprostategroup
AT youngm allelicimbalanceinfamilialandsporadicprostatecancerattheputativehumanprostatecancersusceptibilitylocushpc1crcbpgukfamilialprostatecancerstudycollaboratorscancerresearchcampaignbritishprostategroup
AT corbishleyc allelicimbalanceinfamilialandsporadicprostatecancerattheputativehumanprostatecancersusceptibilitylocushpc1crcbpgukfamilialprostatecancerstudycollaboratorscancerresearchcampaignbritishprostategroup
AT kirbyrs allelicimbalanceinfamilialandsporadicprostatecancerattheputativehumanprostatecancersusceptibilitylocushpc1crcbpgukfamilialprostatecancerstudycollaboratorscancerresearchcampaignbritishprostategroup
AT dearnaleydp allelicimbalanceinfamilialandsporadicprostatecancerattheputativehumanprostatecancersusceptibilitylocushpc1crcbpgukfamilialprostatecancerstudycollaboratorscancerresearchcampaignbritishprostategroup
AT dowea allelicimbalanceinfamilialandsporadicprostatecancerattheputativehumanprostatecancersusceptibilitylocushpc1crcbpgukfamilialprostatecancerstudycollaboratorscancerresearchcampaignbritishprostategroup
AT ardernjonesa allelicimbalanceinfamilialandsporadicprostatecancerattheputativehumanprostatecancersusceptibilitylocushpc1crcbpgukfamilialprostatecancerstudycollaboratorscancerresearchcampaignbritishprostategroup
AT kellyj allelicimbalanceinfamilialandsporadicprostatecancerattheputativehumanprostatecancersusceptibilitylocushpc1crcbpgukfamilialprostatecancerstudycollaboratorscancerresearchcampaignbritishprostategroup
AT eelesra allelicimbalanceinfamilialandsporadicprostatecancerattheputativehumanprostatecancersusceptibilitylocushpc1crcbpgukfamilialprostatecancerstudycollaboratorscancerresearchcampaignbritishprostategroup